南模生物
(688265)
| 流通市值：25.11亿 | | | 总市值：25.11亿 |
| 流通股本：7796.35万 | | | 总股本：7796.35万 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 88,396,140.55 | 381,239,513.99 | 264,848,483.4 | 176,851,264.77 |
| 营业收入 | 88,396,140.55 | 381,239,513.99 | 264,848,483.4 | 176,851,264.77 |
| 二、营业总成本 | 94,524,575.57 | 398,788,336.81 | 296,662,616.31 | 195,649,343.42 |
| 营业成本 | 45,096,068.5 | 207,247,055.01 | 149,290,455.67 | 98,814,037.62 |
| 税金及附加 | 663,981.16 | 3,863,669.48 | 2,202,404.24 | 1,827,354.74 |
| 销售费用 | 15,287,149.06 | 58,012,150.27 | 45,627,932.27 | 30,150,216.02 |
| 管理费用 | 13,094,716.15 | 53,595,460.75 | 39,826,209.06 | 24,660,099.43 |
| 研发费用 | 19,755,542.27 | 74,981,116.58 | 57,232,634.76 | 38,804,681.16 |
| 财务费用 | 627,118.43 | 1,088,884.72 | 2,482,980.31 | 1,392,954.45 |
| 其中:利息费用 | 718,427.15 | 3,801,010.43 | 3,054,903.99 | 2,165,704.27 |
| 其中:利息收入 | 599,033.92 | 1,834,994.79 | 1,191,560.45 | -759,110.91 |
| 加:公允价值变动收益 | 5,422,190.03 | 19,301,458.69 | 15,840,269.92 | 10,434,071.97 |
| 加:投资收益 | 104,414.02 | 1,041,919.05 | 714,176.57 | 714,176.57 |
| 资产处置收益 | - | 20,207.24 | -7,835.19 | -7,835.19 |
| 资产减值损失(新) | -1,288,538.88 | -844,076.86 | -1,332,490.25 | -1,453,100.06 |
| 信用减值损失(新) | -2,431,685.83 | -4,746,341.63 | -7,741,601.29 | -6,369,088.02 |
| 其他收益 | 2,082,310.25 | 5,563,627.94 | 3,532,676.1 | 2,361,596.39 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -2,239,745.43 | 2,787,971.61 | -20,808,937.05 | -13,118,256.99 |
| 加:营业外收入 | - | 57,335.39 | 45,912.99 | 45,912.99 |
| 减:营业外支出 | 50,100 | 116,677.41 | 55,474.79 | 55,128.74 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -2,289,845.43 | 2,728,629.59 | -20,818,498.85 | -13,127,472.74 |
| 减:所得税费用 | -1,323,026.38 | -3,766,874.46 | -5,623,142.6 | -3,983,899.52 |
| 六、净利润 | -966,819.05 | 6,495,504.05 | -15,195,356.25 | -9,143,573.22 |
| 持续经营净利润 | -966,819.05 | 6,495,504.05 | -15,195,356.25 | -9,143,573.22 |
| 归属于母公司股东的净利润 | -966,819.05 | 6,495,504.05 | -15,195,356.25 | -9,143,573.22 |
| (一)基本每股收益 | -0.01 | 0.08 | -0.2 | -0.12 |
| (二)稀释每股收益 | -0.01 | 0.08 | -0.2 | -0.12 |
| 八、其他综合收益 | -43,265.75 | 341,360.49 | -227,518.56 | 174,186.54 |
| 归属于母公司股东的其他综合收益 | -43,265.75 | 341,360.49 | -227,518.56 | 174,186.54 |
| 九、综合收益总额 | -1,010,084.8 | 6,836,864.54 | -15,422,874.81 | -8,969,386.68 |
| 归属于母公司股东的综合收益总额 | -1,010,084.8 | 6,836,864.54 | -15,422,874.81 | -8,969,386.68 |
| 公告日期 | 2025-04-29 | 2025-04-29 | 2024-10-31 | 2024-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |